Free Trial
NASDAQ:SYRS

Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis

Syros Pharmaceuticals logo
$0.0016 +0.00 (+33.33%)
As of 08/1/2025 03:52 PM Eastern

About Syros Pharmaceuticals Stock (NASDAQ:SYRS)

Key Stats

Today's Range
$0.0012
$0.0022
50-Day Range
$0.00
$0.03
52-Week Range
$0.00
$0.10
Volume
6,723 shs
Average Volume
213,055 shs
Market Capitalization
$42.93 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.33
Consensus Rating
Hold

Company Overview

Syros Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

SYRS MarketRank™: 

Syros Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Syros Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Syros Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Syros Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Syros Pharmaceuticals are expected to decrease in the coming year, from ($2.94) to ($2.97) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Syros Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Syros Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Syros Pharmaceuticals has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.40% of the outstanding shares of Syros Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Syros Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Syros Pharmaceuticals has recently decreased by 9.13%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Syros Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Syros Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.40% of the outstanding shares of Syros Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Syros Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Syros Pharmaceuticals has recently decreased by 9.13%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    Only 3 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Syros Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.26% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    91.47% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Syros Pharmaceuticals' insider trading history.
Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SYRS Stock News Headlines

This Social Security Shift Could Boost Benefits by 400%
If you currently collect Social Security—or plan to in the future—this may be one of the most important updates you'll ever see. A new initiative, linked to President Trump's Executive Order #14196, has the potential to do more than just protect Social Security from collapse... According to renowned investor Louis Navellier, it could increase benefits by as much as 400%.
Syros Pharmaceuticals trading resumes
Syros Pharmaceuticals Plans to Wind Down Operations
See More Headlines

SYRS Stock Analysis - Frequently Asked Questions

Syros Pharmaceuticals' stock was trading at $0.2298 on January 1st, 2025. Since then, SYRS stock has decreased by 99.3% and is now trading at $0.0016.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) released its quarterly earnings data on Thursday, October, 31st. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.08.
Read the conference call transcript
.

Syros Pharmaceuticals's stock reverse split before market open on Monday, September 19th 2022.The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Top institutional investors of Syros Pharmaceuticals include FNY Investment Advisers LLC. Insiders that own company stock include Jason Haas, Conley Chee, Timothy Tyson, David Roth, Richard A Young, Eric R Olson and Nancy A Simonian.
View institutional ownership trends
.

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Syros Pharmaceuticals investors own include Salesforce (CRM), QUALCOMM (QCOM), Bank of America (BAC), Bristol Myers Squibb (BMY), Pfizer (PFE), Twilio (TWLO) and AbbVie (ABBV).

Company Calendar

Last Earnings
10/31/2024
Today
8/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SYRS
CIK
1556263
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$1.00
Potential Upside/Downside
+208,233.3%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$164.57 million
Net Margins
N/A
Pretax Margin
-25,275.20%
Return on Equity
-3,369.56%
Return on Assets
-97.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.25
Quick Ratio
2.25

Sales & Book Value

Annual Sales
$386 thousand
Price / Sales
0.11
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.79 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
26,832,000
Free Float
23,542,000
Market Cap
$42.93 thousand
Optionable
Optionable
Beta
1.31

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:SYRS) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners